摘要
炎症性肠病(inflammatory bowel disease,IBD)是一类病因尚不明确的慢性炎症性肠道疾病,目前主要治疗药物包括氨基水杨酸类、糖皮质激素、免疫抑制剂及生物制剂等.随着科技进步及对疾病的深入研究,对生物制剂的作用靶点研究也越来越多,包括有肿瘤坏死因子-α、Janus激酶、白细胞介素、肠道整合素等.维得利珠单抗作为一种人源化的整合素拮抗剂选择性抑制整合素α4β7与黏膜地址素细胞黏附分子-1(mucosaladdressin cell adhesion molecule-1,MAdCAM-1)相互作用,阻断淋巴细胞向肠道迁移来减轻肠道炎症达到治疗效果,本文对维得利珠单抗治疗炎症性肠病的作用机制、疗效和临床应用作一综述.
Inflammatory bowel disease is a kind of chronic inflammatory disease of the gastrointestinal tract with unclear etiology.At present,its main therapeutic drugs include aminosalicylates,glucocorticoids,immunosuppressive agents,and biological agents.With the deepening study of the disease and the progress of science and technology,there have been more and more studies on the targets for biological agents,including tumor necrosis factor-α,Janus kinase,interleukin,intestinal integrin,etc.As a humanized integrin antagonist,vedolizumab can selectively inhibit the interaction between integrinα4β7 and mucosal addressin cell adhesion molecule-1,and block the migration of lymphocytes to the intestinal tract to alleviate the intestinal inflammation,so as to achieve the therapeutic effect.This article reviews the mechanism,clinical efficacy,and application of vedolizumab in the treatment of inflammatory bowel disease.
作者
靳琦文
王晓娣
Qi-Wen Jin;Xiao-Di Wang(Peking University China-Japan Friendship School of Clinical Medicine,Beijing 100029,China;Department of Gastroenterology,China-Japan Friendship Hospital,Beijing 100029,China)
出处
《世界华人消化杂志》
CAS
2021年第5期248-255,共8页
World Chinese Journal of Digestology
关键词
炎症性肠病
生物制剂
维得利珠单抗
整合素拮抗剂
肠道选择性
Inflammatory bowel disease
Biological agents
Vedolizumab
Integrin antagonists
Intestinal selectivity
